The trajectory of Viagra presents a complex picture for shareholders. While the initial release generated significant gains, the end of its patent opened the door to off-brand alternatives, dramatically diminishing market share. This creates a unique challenge for pharmaceutical companies depending on related blockbuster products, suggesting that a

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in income, its patent expiration created a deluge of knock-off medications, significantly eroding its position . While some pharmaceutical companies may seek to capitalize on similar conditions , the pres